Who is sponsoring NCT00314288?

NCT00314288 is sponsored by EMD Serono.

What condition does NCT00314288 study?

NCT00314288 studies Parkinson's Disease, Dyskinesia.

What is the status of NCT00314288?

NCT00314288 is currently COMPLETED.

Last reviewed 2017-01-19 · How we verify

A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

NCT00314288 Phase 2 COMPLETED

The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).

Details

Lead sponsor	EMD Serono
Phase	Phase 2
Status	COMPLETED
Enrolment	360
Start date	2002-07
Completion	2003-07

Conditions

Parkinson's Disease
Dyskinesia

Interventions

Sarizotan HCl

Countries

United States, Belgium, Bulgaria, Canada, France, Germany, Hungary, Portugal, Romania, South Africa, United Kingdom